Article

Exon-centric regulation of pyruvate kinase M alternative splicing via mutually exclusive exons

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Journal of Molecular Cell Biology (Impact Factor: 8.43). 11/2011; 4(2):79-87. DOI: 10.1093/jmcb/mjr030
Source: PubMed

ABSTRACT Alternative splicing of the pyruvate kinase M gene (PK-M) can generate the M2 isoform and promote aerobic glycolysis and tumor growth. However, the cancer-specific alternative splicing regulation of PK-M is not completely understood. Here, we demonstrate that PK-M is regulated by reciprocal effects on the mutually exclusive exons 9 and 10, such that exon 9 is repressed and exon 10 is activated in cancer cells. Strikingly, exonic, rather than intronic, cis-elements are key determinants of PK-M splicing isoform ratios. Using a systematic sub-exonic duplication approach, we identify a potent exonic splicing enhancer in exon 10, which differs from its homologous counterpart in exon 9 by only two nucleotides. We identify SRSF3 as one of the cognate factors, and show that this serine/arginine-rich protein activates exon 10 and mediates changes in glucose metabolism. These findings provide mechanistic insights into the complex regulation of alternative splicing of a key regulator of the Warburg effect, and also have implications for other genes with a similar pattern of alternative splicing.

Download full-text

Full-text

Available from: Martin Akerman, Jul 28, 2015
0 Followers
 · 
350 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mitochondria are semi-autonomous organelles that play essential roles in cellular metabolism and programmed cell death pathways. Genomic, functional and structural mitochondrial alterations have been associated with cancer. Some of those alterations may provide a selective advantage to cells, allowing them to survive and grow under stresses created by oncogenesis. Due to the specific alterations that occur in cancer cell mitochondria, these organelles may provide promising targets for cancer therapy. The development of drugs that specifically target metabolic and mitochondrial alterations in tumor cells has become a matter of interest in recent years, with several molecules undergoing clinical trials. This review focuses on the most relevant mitochondrial alterations found in tumor cells, their contribution to cancer progression and survival, and potential usefulness for stratification and therapy.
    Biochimica et Biophysica Acta 04/2012; 1826(1):238-54. DOI:10.1016/j.bbcan.2012.04.005 · 4.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Metabolic adjustment to low oxygen exposure (hypoxia) in the white shrimp Litopenaeus vannamei implies a shift to anaerobic metabolism. Lactate dehydrogenase (LDH) is a key enzyme of the anaerobic metabolism described in most organisms. The structure and expression of the LDH gene, as well as the LDH isoenzymes in marine crustacean are not well defined. In the present study we characterized a gene that codes for two LDH subunits, measured their expression and detected the isoenzymes in tissues from white shrimp. We also silenced the transcriptional activator hypoxia inducible factor 1 (HIF-1) to elucidate the regulation of LDH in tissues from white shrimp in response to hypoxia. The complete LDH gene coding sequence is 7571 bp (LvanLDH) and encodes two different LDH subunits (LDHvan-1 and LDHvan-2) generated by alternative splicing and composed of 332 amino acids with conserved domains important for the function and regulation. Phylogenetic analysis shows that LvanLDH -1 and -2 are closer to the invertebrate counterparts. The LDHvan-1 transcript increased 2.5-fold after hypoxia in gills but not in hepatopancreas, while the LDHvan-2 transcript decreased 14-fold in muscle but not in gills and hepatopancreas. Three bands with LDH activity of ∼60–90 kDa were detected in hepatopancreas, while one band of ∼140 kDa was detected in gills and muscle. The silencing of HIF-1 blocked the increase of LDH mRNA and activity produced by hypoxia in gills. These results demonstrate a single gene for LDH (LvanLDH) that by alternative splicing generates two different LDH subunits (LDHvan-1 and LDHvan-2) that are expressed in a tissue-specific manner during hypoxia via the HIF-1 pathway.
    Biochimie 05/2012; 94(5):1250-60. DOI:10.1016/j.biochi.2012.02.015 · 3.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: The interpretation of high-throughput profiling data depends on the pathway analysis database. Currently, pathway analysis often has to rely on a set of interactions and pathways measured in every possible human tissue, due to insufficient knowledge about interactions and pathways in the context of the profiling experiment. However, a recent global scale analysis of human tissue proteomes and interactomes reveals significant differences among tissues, suggesting that interaction and pathway data that are used out of biological context are the major source of inaccuracies and noise in the analysis of profiling data. AREAS COVERED: In this review, the major classes of biological context used for experimental detection of molecular interactions and pathways in molecular biology are described. Furthermore, the author reviews methods for predicting biological interactions in order to evaluate the applicability of various contextual interaction data in pathway analysis. Using the results from recent publications that study large-scale tissue composition, the article provides an estimation of the gain in pathway analysis accuracy if only the interactions predicted for the context of a molecular profiling experiment are used, relative to the analysis performed with a context-independent knowledge base. EXPERT OPINION: It is of the author's opinion that the major source of inaccuracy in pathway analysis is the lack of knowledge about tissue-specific transcriptional regulation. It is therefore suggested that the accuracy of the analysis can be substantially improved if only context-specific interactions and pathways are used for interpretation.
    Expert Opinion on Drug Discovery 06/2012; 7(8):659-66. DOI:10.1517/17460441.2012.691877 · 3.47 Impact Factor
Show more